Phase II PI3K inhibitor in relapsed, indolent or aggressive NHL

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-002602-52

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The objective of this study is to evaluate the efficacy and safety of copanlisib in patients with indolent or aggressive Non-Hodgkin’s Lymphoma (NHL) who have progressed after standard therapy. The objective of study part B is to evaluate the efficacy and safety of copanlisib in patients with indolent B-cell NHL relapsed after, or refractory to widely used approved therapies in standard practice.


Critère d'inclusion

  • Patients with relapsed, indolent or aggressive Non- Hodgkin’s lymphomas or patients with indolent B-cell Non-Hodgkin's lymphoma relapsed after or refractory to standard therapy